CM PLUS™ CETYL MYRISTOLEATE

PRODUCT RATIONALE

OVERVIEW

Cetyl myristoleate, (CMO) has achieved truly amazing results in alleviating the symptoms of osteo and rheumatoid arthritis and a host of other chronic conditions. It has widely achieved good results with many autoimmune conditions including multiple sclerosis, psoriasis and prostate problems.

Success is further improved by following the dietary recommendations that help the CMO to be better absorbed by the body, and by products that help repair the previously damaged cartilage.

Many doctors have gone to print and expressed extremely forthright and positive views of CMO, using words like "miraculous" and "cure" quite liberally. They are backed by findings of clinical research, their own experiences with patients, and in some cases of the help they personally have received for their own chronic conditions. The experience of doctors and thousands of users and clinical tests is that CMO is free of harmful side effects and non-toxic even in large quantities. CMO is naturally derived from food sources.

CMO has been shown to improve the symptoms of and even put into remission: rheumatoid and osteoarthritis, ankylosing spondylitis, Reiter's syndrome, Behcet's syndrome, Sjögren's syndrome and psoriasis. It has also been found to relieve various types of back pain of undetermined origin (probably arthritis related).

Not everybody is guaranteed to receive help from CMO. However, a large number can receive enough help for CMO to truly alter their everyday life. After witnessing this Dr. Hunt states "CMO is the nutritional discovery of the 20th century" (Boom—You're Well).

CMO is the oral analogue of cetyl myristoleate, that has very high bio-availability. In room temperature cetyl myristoleate is waxy oil, which is not at all well absorbed by the body when orally taken. It works best when injected directly into the joint - a choice that is not normally available. In contrast CMO - cerasomal-cis-9-cetylmyristoleate - does absorb very well and enables the cetyl myristoleate component to reach where it can do best benefit.

Cetyl myristoleate is fatty acid ester that appears to have the same characteristics as the essential fatty acids linoleic and alpha linoleic acids, except stronger and longer lasting. These fatty acids are referred to as "essential" because the human body cannot make them and we must ingest them in our diets. In Boom—You're Well, Dr. Douglas Hunt states, "Cetyl myristoleate will probably be seen as the most important find of the 20th Century."

There is absolutely no doubt that CMO, the oral analogue of cetyl myristoleate, is beneficial to alleviating arthritis and host of other chronic ailments. There is clinical evidence, doctor's reports and a large mass of users telling us that it has worked miracles to reduce their pain and improve their mobility. This is achieved free of harmful side effects and usually by completing only a single 18-gram course.

Quite expectedly, with a product that has performed so well for so many people, it has led to exaggerated claims, which although may be true for some people are not universally applicable. Chief among these is that only a single course needs to be taken, ever! This is not entirely true for everyone as some people have to repeat the 15-day course before full effects of the CMO are achieved. Some people also find that some time afterwards (6-24 months), their (former) symptoms reappear. These are usually settled by taking a few capsules of CMO. These observations may be listing the shortcomings of CMO as a "miracle cure". However, to the beleaguered chronic sufferer, these "shortcomings" hardly matter as the amount of benefit offered by CMO is unequalled - either in the "natural medicines" field or by any drug.

The common consensus of why cetyl myristoleate has taken so long to come to the public domain is that large pharmaceuticals have been unwilling to market the product - being natural, there is not the same profit in it as there would be in a proprietary drug.

Clinical Studies:

Two major clinical studies have been carried out on cetyl myristoleate. The first at the San Diego Clinic, reported in detail further on in this document, applied CMO to 48 patients suffering from mild to crippling osteo and rheumatoid arthritis. All but two, showed remarkable improvement. The two that did not were found to have liver problems and it was surmised that, these two failed to properly absorb CMO. In general, failure to properly absorb CMO seems to be a major cause in it not working effectively.

Another clinical study was reported by Dr H Siemandi MD. This was a double blind study featuring nearly 400 people. It was supervised by rheumatologists and other specialists. The findings were that for 87% of the patients who took cetyl myristoleate (and a supporting formula of other nutrition) there was a significant improvement (as assessed by their physician based on reduced pain and mobility).

Discovery:

Cetyl myristoleate was discovered by a researcher working in the US National Institutes of Health back in the early 1970's. Working on his own, for lack of funding, the researcher had found it impossible to (artificially) induce arthritis in a certain strain of Swiss Albino Mice and after much further research he successfully extracted the substance that was "protecting" the mice. Further experimentation showed that rats injected with cetyl myristoleate were protected from artificially induced arthritis, while other rats, which were not first given cetyl myristoleate, developed the arthritis.

Many years later, Harry Diehl developed arthritis - and successfully reversed the condition by injecting cetyl myristoleate near the joint. His doctor was so impressed with the recovery that he persuaded Harry Diehl to publish a research paper, one of whose calls was for further work to find an oral analogue of cetyl myristoleate that could be easily absorbed by the body. The San Diego Clinic took up this cause producing an orally administered, highly bio-available analogue of cetyl myristoleate, cerasomal-cis-9-cetylmyristoleate, trade name, CMO. This product was used in clinical trials described further on and it produced some astounding results.

Today 25 years after the original discovery, in the USA, tens of thousands of people are reported to have used CMO to good effect. The majority of these being in the last two years since CMO became commercially available.

Experience of doctors and clinical trials have shown that the potency of CMO can be further improved by combining it with certain other items. In one double blind clinical trail which proved that cetyl myristoleate was of significant benefit, it was also shown that when it is combined with glucosamine, sea cucumber extracts and other items, the benefits were even greater.

Questions and Answers:

The following questions were answered by the doctors, staff and research associates of the San Diego Clinic.

What makes CMO different from all the other remedies?

Does that mean a person takes CMO only once and that's it?

Does it work for both rheumatoid and osteo-arthritis?

Does CMO improve joint mobility?

Does it stop arthritis pain?

Does CMO reduce inflammation?

How long before it takes effect?

Will it correct deformities?

What about really severe cases?

What about joints where the cartilage is completely worn away?

Does it work for everyone?

Can I continue with my usual medications while taking CMO?

Do I have to go on a special diet?

What about exercise?

Is it okay to exercise? Is it expensive?

Is age a factor?

What causes arthritis?

How does CMO work?

Is CMO harmful in any way?

What is CMO? Where does it come from?

Is CMO used for any other ailments?

Q: What makes CMO different to other remedies?

CMO is not a pain reliever, nor is it a steroid or anti-inflammatory. It is an immunomodulator. There's never been anything like it before for arthritis. Instead of treating the symptoms of pain and inflammation, CMO acts against the cause of arthritis &endash; the erroneously programmed Memory T Cells of your own immune system that cause the attacks against your joints. Once the attacks on your joints are halted the symptom of pain and inflammation is promptly remedied.

Q: Does that mean a person takes CMO only once and that's it?

Yes. Most afflicted persons need to take the capsules for only a couple of weeks to be free of arthritis symptoms forever. No further medication is ever necessary, not even CMO.

Q: Does it work for both rheumatoid and osteo-arthritis?

Both types respond equally well. It also works for most other types of arthritis such as those associated with Ankylosing Spondylitis. Reiter's syndrome. Behcet's syndrome, Sjogren's syndrome and Psoriasis. It has also been found to relieve various types of back pain of undetermined origin probably arthritis related)

Q: Does CMO improve joint mobility?

Yes, it can! If the joint can be moved, joint mobility may be improved. But if the bones have fused and grown together, only surgery can help those particular joints.

Q: Does it stop arthritis pain?

Arthritis pain will disappear completely in almost every instance. In a few extreme cases pain was reduced by only 70% to 90%, which was still of such major benefit that it allowed the persons to function normally again.

Q: Does CMO reduce inflammation?

Yes, and it does so very effectively. The pressure in the joints caused by the inflammation is the major cause of stiffness and pain.

Q: How long before it takes effect?

Most people can begin to feel relief within a couple of weeks. Others may need several months.

Q: Will it correct deformities?

Yes. Deformed fingers and toes are often caused by inflammation which swells joints and pushes the bones out of place. Reduction of the swelling alone improves appearance dramatically and often allows the dislocated bones to return to their normal positions. Extreme cases may require some physical therapy.

Q: What about really severe cases?

Even most persons previously confined to bed or to wheelchairs have responded dramatically and are now no longer dependent on others for care. A number of these cases received additional benefit from repeating the treatment one more time. A few others found that physical therapy or exercise programs also helped.

Q: What about joints where the cartilage is completely worn away?

Unless the bones have fused together, the usual problem is not lack of mobility, but pain. The majority of such drastic cases have responded favorably resulting in painless movement, even in the knees.

Q: Does it work for every one?

No. CMO has been able to help many individuals, but not everyone will see an improvement in their arthritic symptoms. We all have different bodies, lifestyles, eating habits, etc., therefore the results will vary. Digestive problems or liver function impairment, can sometimes interfere with success.

Q: Can I continue with my usual medications while taking CMO?

Yes, but after a few days you probably will not need them. However, it's best to avoid steroids if possible.

Q: Do I have to go on a special diet?

Alcohol, chocolate, and tea should be avoided. Some users find that avoiding or limiting other foods helps improve effectiveness. A recommended diet accompanies this product, but it only need be followed for a few weeks. Many people take digestive enzymes with CMO to help them absorb it. Afterwards, there are no restrictions.

Q: Will I have to exercise?

The absence of pain and return of joint mobility is so profound that normal activities will follow quite naturally. No special exercises are necessary. Actually, the usual tendency is to overindulge in the new found freedom, sometimes temporarily resulting in soreness of muscles previously unused.

Q: Is it okay to exercise?

Yes. Many people want to lose weight and or rebuild strength once they are free to do so again painlessly. But, as with all sound fitness programs, it's best to do so gradually. Your body will need time to adjust.

Q: Is it expensive?

The cost of treatment is very modest. Most arthritis victims are already spending more on pain and anti-inflammation medications in just a few months. Since you usually need to take only one set of CMO capsules, it actually saves thousands of dollars in the long run.

Q: Is age a factor?

Not really. All ages respond well. Although arthritis becomes far more common with advancing age, even very young children are sometimes afflicted.

Q: What causes arthritis?

The numerous theories about what causes arthritis have filled hundreds of volumes. But one thing we do know is that the arthritic process is regulated by Memory T Cells which have been erroneously programmed, causing attacks on your own joints and cartilage.

In osteo-arthritis, this faulty programming usually results from physical damage (like a fall, sports injury, vehicle accident, repeated operation of vibrating machinery, long-term strenuous physical work or sports activities, and continuous repetitive motions of certain joints) etc. The damage results in an immune response involving the memory T cells producing attacks against the affected joints. Unfortunately, there's no stop or end command given and the attack continues against healthy cartilage and joints as well. That's why arthritis is called an auto-immune disease, our own body is attacked by our own immune cells.

Although the various forms of rheumatoid arthritis are usually caused by some ineffective micro-organism. Memory T cells is again involved in the same arthritic process. Without CMO it continues to worsen.

Q: How Does CMO Work?

CMO corrects the root cause of arthritis by erasing the memory of the badly programmed memory T cells. Once the destruction of your joints is halted, your body can begin its repair process without interference, and joints begin to normalize. Although the major benefits come promptly, minor improvements continue even for several months after finishing CMO. With the pain and inflammation relieved, the joints can function again quite normally. Despite minor physical damage to bones as a result of long affliction, perfectly normal joint function usually returns regardless.

Q: Is it harmful in any way?

CMO studies began at the US National Institutes of Health more than 20 years ago. Recently, clinical applications studies were conducted in San Diego. No harmful short or long-term effects were ever observed in humans, or in laboratory animals even at extremely high doses. Similar substances have long been used in common foods including cheese and chocolate, and even in medicines and cosmetics. It is a perfectly safe and naturally derived substance.

Q: What is CMO? Where does it come from?

Cerasomal-cis-9-cetylmyristoleate is the biomedical name. CMO is the trade name. It is a completely natural substance found in certain animals such as cows, beavers, mice, and whales and has recently been produced from the African Kombo nut. As supplied in capsules, it is a naturally derived, highly purified and refined waxy ester prepared for oral administration.

Q: Is CMO used for any other ailments?

Current studies include CMO as a part of therapeutic protocol for other disorders with auto-immune components including multiple sclerosis, leukemia, lupus, emphysema, certain cancers, benign prostrate hyperplasia, silicon breast disease, and especially asthma. It also works for dogs, cats, horses and other animals.

Clinical Studies:

A number of clinical studies and observations are under way in various clinics and institutions.

Currently, a prominent University in United States is studying CMO. It is in the preliminary stages and 12 subjects are being observed. Their formal double blind study will include before and after X-rays, MRI's blood work on 200 patients.

There is also a licensed Canadian medical research firm that conducted an 1800 patient study, the result of which are not yet public. Their study shows that CMO is effective on 87% of the people that use it.

It is also reported that another university in the USA is studying the efficacy of CMO with animals. CMO is incredibly successful when used with animals (cats, dogs, horses, etc. have all been known to give incredible success.) This exceptionally high rate of success (virtually nil failures) is believed to result from the greater digestive capabilities of these animals (hence better absorption of CMO) compared to humans.

Further details of two substantial studies on CMO are given below. Study 1: The Effect of cis-9-Cetyl Myristoleate CMO and ajunctive therapy on the course of arthritic episodes in patients with various auto-immune diseases characterised by the common terminology "arthritis" and "psoriasis". Study 2: A Study on Dose Effectiveness and Patient Response Conducted by the San Diego Clinic.

STUDY 1

The Effect of cis-9-Cetyl Myristoleate CMO and adjunctive therapy on the course of arthritic episodes in patients with various auto-immune diseases characterized by the common terminology "arthritis" and "psoriasis".

A randomised clinical trial by Dr. H. Siemandi, MD, et al.

The following are selected extracts.

CONCLUSION: Cis-9-cetyl myristoleate treatment and cis-9-cetyl myristoleate plus GH, SC & HC (referring to nutritional supplements glucosamine hydrochloride (GH), sea cucumber (SC) and hydrolyzed cartilage (HC)) were demonstrated to offer significant benefits over the placebo in the prevention of arthritic episodes. It was further determined that these results could not be obtained with other standard arthritic therapies based upon exhaustive reviews of patient records prior to opening of the study. Cis-9-cetyl myristoleate and cis-9-cetyl myristoleate plus GH, SC & HC treatment also seems to permit some relief to autoimmune inflammatory diseases which may prove to be long-term. This finding could provide additional evidence for the theory, reflected by the earlier anecdotal evidence as well as some animal studies, that cis-9-cetyl myristoleate and cis-9-cetyl myristoleate plus GS, SC & HC may prove to be of major benefit in the future treatment of autoimmune diseases.

Study Objective: Recent published reports offer anecdotal evidence (publication speak for "actual experience of users") that cis-9-cetyl myristoleate may provide significant amelioration of various arthritic conditions. We set out to perform controlled studies to determine if this material was efficacious, either in the short term, or in some measurable manner, over a much longer period.

Methods: A prospective, randomised study design was used to allocate patients to receive cis-9-cetyl myristoleate, cis-9-cetyl myristoleate plus glucosamine hydrochloride (GH), sea cucumber (SC) and hydrolyzed cartilage (HC) and a placebo.

Study design: The study was a 32 week (8 week cycle, 4 in-hospital & 4 in follow-up), multicenter, double-blind, randomised, placebo-controlled parallel trial that compared the efficacy of cis-9-cetyl myristoleate alone, and cis-9-cetyl myristoleate plus GS, SC & HC, administered over a period of 30 days, with placebo, for the treatment of various forms of autoimmune diseases commonly characterised as arthritis and psoriasis. Out of a dose of 90 grams of total fatty acid esters, 18 grams constituted cis-9-cetyl myristoleate. Those study patients who received the support nutrients GS, SC, & HC were given a total dosage of 18 grams each of these nutrients.

The study was conducted under the auspices of the Joint European Hospital Studies Program. This study was designed by a committee, which consisted of rheumatologists and biostatisticians experienced in the development and execution of clinical trials. Oversight of the study was accomplished by an executive committee, composed of the primary researcher and primary statistician, selected participating investigators, consultants; and an independent sight committee consisting of two experienced federally controlled, state health department rheumatologists and one state health department biostatistician.

Results Summary: At the start of this study, the duration, severity, and pattern of arthritic episodes were found to be similar in the 3 treatment groups. At the end of the study it was found that the number of arthritic episodes was significantly reduced, and the duration of episode-free time was significantly prolonged, in the two cis-9-cetyl myristoleate groups compared with the placebo group.

At the end of eight weeks, the response rates were 63.3% with the cis-9-cetyl myristoleate group and 87.3% in the cis-9-cetyl myristoleate plus GS, SC & HC group and only 14.5% in the placebo group.

Joint swelling scores improved in 47.2% in patients using cis-9-cetyl myristoleate alone and 77.2% in patients using cis-9-cetyl myristoleate plus GS, SC & HC. Patients experiencing worsening or no reaction totalled 1.0% in all groups, compared with improvement of 21.1% in placebo group.

DETAILS

Patient population: Four hundred thirty-one patients entered the study. Of these, 106 were randomised to receive cis-9-cetyl myristoleate, 84 were randomised to receive cis-9-cetyl myristoleate plus GS, SC & HC; 226 received a placebo. Fifteen psoriatics received cis-9-cetyl myristoleate plus GS, SC & HC, plus CM-25% concentration topical at a 3X quantity ratio. Even though the study was sponsored by the owners of the respective private hospitals, recruitment was not limited to the typical fee-paying patients. Approximately 27% of the patients were actively recruited in the respective local area. Despite a prolonged accrual period and careful screening, the loss of approximately 11% of the starting participants occurred largely because of the inability to stop the use of tobacco and/or caffeinated beverages

OUTCOME - how "response" was graded

Clinical assessment: Outcome measures of disease activity and therapeutic efficacy were obtained at the time of screening (not more than four weeks before study entry), randomization at week zero, and thereafter at weeks 1, 2, 3, and 4. Outcome measures included a variety of patient-reported, clinical, laboratory and radiographic assessments. Patient self-assessment measures included morning stiffness, night pain, patient overall assessment and Mobility Functional Index as determined by this published procedure. Clinical assessment measures included joint counts, dactylitis, Enthesopathy Index, Spondylitis Articular Index, chest expansion, modified Schober's test, and finger-to-floor test as detailed elsewhere in this paper. Additionally, the presence of symptomatic keratoderma, phalangeal and digital deformation as measured from a normal range of vertical protrusion at rest were measured. These tests, singularly and collectively were then compiled into a patient-by-patient qualitative scale as; none = O, mild = 1, moderate = 2, severe = 3 and very severe =4.

Laboratory assessment: Laboratory evaluation included a urinalysis and complete blood cell count, with leukocyte differential and reticulocyte count. Chemical surveys and a Westergren erythrocyte sedimentation rate (ESR) determination were done at every visit by secondary researchers daily in the two hospital settings. The C-reactive protein (CRP) level was evaluated at the first and last day of the hospital stay. At the screening times, blood was drawn for HLA-B27 typing and RF and ANA determinations.

Radiology assessment: At the screening visit, all patients had the following radiographs performed: anteroposterior views of the pelvis and oblique views of the sacroiliac joints. Adverse drug reactions (ADR's). Patients were screened for ADR's at every secondary researcher's visit. Patients were withdrawn from the study medication if any of the following were found; WBC less than 3000/mm3, absolute polymorphonuclear count less than 100000/mm3, acute or progressive decrease in hemoglobin or hematocrit, proteinuria less than 500 mg. for 24 hours, drug fever or significant rash. Biostatistical considerations. Each patient was classified as a treatment responder or nonresponder based on the following definition. Assessment measures were selected a priori, and criteria for clinical improvement and worsening were defined for each patient self-assessment and physician assessment (improvement category); joint pain/tenderness score and joint swelling score (improvement = decrease by 30%; worsening = increase by 30%). Treatment response was then defined as improvement in at least 2 of these 4 measures, one of which must be joint pain/tenderness or swelling, and ITO worsening any of the 4 measures. The study was designated with a 90% power for detecting a placebo response rate of 30% compared with a cis-9-cetyl myristoleate and cis-9-cetyl myristoleate plus GS, SC & HC response rate of 50%, assuming a 10% withdrawal rate. This resulted in a target sample size of 431 patients with an actual sample size of 382.

In short, the analytical method was the change in primary and secondary outcome measures from baselines to the last available follow-ups analyzed using t-tests for continuous data and chi-square tests for ordinal and categorical data. Mixed-model analyses were done to characterize the response patterns over time using SAS PROC MIXED for continuous data and a program named MIXOR for categorical and ordinal data. All other analyses were conducted using SAS version 6.08. All statistical tests were two-sided and P0.05 was the criterion for statistical significance.

AUTHOR'S DISCUSSION POINTS

The results of this trial suggest that cetyl myristoleate and cetyl myristoleate supporting formulas may be beneficial in the treatment of many forms of arthritic based diseases, including: psoriatic arthritis. The definition of response was determined a priori and included assessment of joint pain/tenderness and swelling as well as patient and physician overall assessments. Cetyl myristoleate and supporting formulas produced the best treatment response by a factor of 72.8% more patients than did placebo. Considering the components of response individually cetyl myristoleate and supporting formulas resulted in 70.3% more patients having improved as assessed by physician, and 56.1% more having improved joint swelling. Therefore, while the amount of treatment response using cetyl myristoleate and cetyl myristoleate and supporting formulas seems to be consistent with the treatment affects on joint counts, it is obvious that there is a statistically significant improvement in the use of the CM with supporting formulas. The time-line based response rate of cetyl myristoleate and cetyl myristoleate supporting formulas, not adequately reflected in data, by patient, showed the majority of patients responding to cetyl myristoleate and cetyl myristoleate supporting formulas did so within the first three weeks. Also, not reflected in the data, was the continued use of cetyl myristoleate and cetyl myristoleate supporting formulas beyond the study time limits and dispensed on request to 21 patients. These 21 patients were determined to have received only marginal benefits from cetyl myristoleate and cetyl myristoleate supporting formulas but one more course of treatment showed responses approximately equal to the first patient response results.

Cetyl myristoleate and cetyl myristoleate supporting formulas were well tolerated in this trial. This finding was not unexpected as cetyl myristoleate and the cetylmyristoleate supporting formula components are naturally occurring and have been used as diet supplementation for many years and are widely available singly and in various combinations. In summary, cetyl myristoleate and cetyl myristoleate supporting formulas appear to be beneficial in the treatment of a wide range of arthritic conditions including long standing and refractive cases.

Correspondence: Humberto Siemandi, MD, Ph.D. Primary research administrator at Hospital SM, Avenido Mazatlan, Rosarito Beach, Baja, California and Institut SM, Kamin Pamorski, Poland.

STUDY 2

A Study on Dose Effectiveness and Patient Response Conducted by the San Diego Clinic

The Purpose: The effectiveness and nontoxicity of CMO (cerasomal-cis-9-cetylmyristoleate) for arthritis symptoms of pain, inflammation, and impaired mobility having been previously established, the purpose of the present study was:

1.) To determine optimum dosage levels for various types of arthritis,

2.) To determine if different dosage levels would be required relative to the severity of each type of arthritis,

3.) To observe response time required for initial and partial relief of symptoms,

4.) To observe response time required for complete relief of symptoms, and

5.) To determine factors influencing subjects who may not respond to the protocol.

The Subjects: Subjects were volunteers treated as outpatients. They presented with osteo-arthritis, rheumatoid arthritis, and other forms of reactive arthritis.

The Study: The study involved 48 subjects. Female subjects (28) ranged from 33 to 82 years of age. Male subjects (20) ranged from 29 to 74 years of age. All races and many ethnic backgrounds were represented. Age, gender, race, and ethnological background appeared to be irrelevant to patient response in this study.

The Protocol: CMO was administered orally in the form of 75mg capsules each morning and evening. The number of capsules and duration of treatment varied for each group of subjects. Subjects were advised to take capsules on an empty stomach with water only; and to avoid tea, chocolate, alcohol, coffee, cola, and other caffeinated drinks for five hours after taking the capsules. Subjects were advised to completely avoid chocolate and alcohol during the entire trial period of two to four weeks duration. With a few exceptions for subjects who could not function without them, steroids were also prohibited. Otherwise diet was not controlled in any way. Subjects were permitted to continue taking their customary pain and non- steroidal anti-inflammatory medications until they were no longer needed. Subjects were asked to visit or call in to report progress at least twice weekly.

The Results: Only two subjects failed to show marked or complete relief of all symptoms of pain and limited mobility normally associated with arthritis. Both of these non-responding subjects had suffered prior hepatic problems: one from alcohol abuse resulting in cirrhosis of the liver; the other, a former professional athlete, presented with considerable liver damage from steroid abuse. Further studies are necessary to determine the role of liver function capacity with respect to this protocol. Liver damage resulting from steroids previously prescribed for arthritis may also prove to be a factor affecting patient response.

Two other subjects showed less than a 75% return of articular mobility. The balance of all subjects reported 80% to 100% return of articular mobility as well as a 70% to 100% decrease of pain. Relief of inflammation frequently resulted in at least partial correction of some deformities. Informal independent trials at clinics, by individual medical doctors, and other health practitioners appear to have brought approximately the same results.

GROUP # 1: Mild to moderately severe osteo-arthritis & reactive psoriatic arthritis

In Group #1, eleven subjects presenting with mild to moderately severe osteo-arthritis and one with reactive psoriatic arthritis were supplied with 16 capsules, two 75mg capsules to be taken each morning and evening for four days. Nine reported about 20% to 30% improvement in articulation and inflammation and about 40% to 50% relief of arthritic pain within 36 hours. In these nine subjects improvement continued rapidly for the next 60 hours, reaching a 70% to 80% overall improvement by the end of the four days. Two of the three latter subjects continued to improve over the following week despite the fact that they were no longer taking the capsules. However, about half of this group experienced the return of some mild arthritic symptoms after about three to five weeks. (Although not included as part of this study, all of the subjects in this group were treated again and their symptoms have not returned.) The patient with reactive psoriatic arthritis also experienced an almost complete reversal of his associated very severe psoriatic skin condition affecting about 20% of his total skin area.

GROUP # 2: Severe to crippling rheumatoid arthritis

In Group #2, nine subjects presenting with severe to crippling rheumatoid arthritis were supplied with 50 capsules to be taken in two series, two 75mg capsules each morning and evening for seven days, with a seven day interval before repeating the same dosage for 5-1/2 more days. Four of these subjects were unable to walk and were accustomed to being transported by wheelchairs. One, her femur being fused at the hip, was unable to achieve a sitting position for wheelchair transport. She could, however, move about slowly on crutches as long as she was accompanied by someone to aid her in maintaining her balance. Otherwise she could only stand or lie down. The remaining four could move about with canes or walkers. All nine subjects presented with pain, inflammation, and marked deformation of nearly all proximal interphalangeal and large joints. Five presented with limited lumbar flexion and pain in the vertebral column. All had difficulty grasping and manipulating common objects.

Within three days of treatment six subjects in the group reported a 30% to 50% decrease in pain and 20% to 30% increase in joint mobility, and three subjects reported little change. Within seven days five subjects reported a 70% to 90% decrease in pain and 70% to 80% increase in joint mobility. Three subjects reported to be totally free of pain with almost complete return of joint mobility and marked improvement in joint deformation. One patient reported no perceptible change.

On the fourteenth day, at the end of the one week interval without treatment, six subjects reported minor continuing improvement; two reported maintaining their improved status, and one continued to show no improvement. Treatment was resumed on the fifteenth day for 5-1/2 more days.

By the end of the treatment period all but two subjects reported to be 90% free of pain with return of 70% to 100% mobility. The fused hip joint remained fused, of course, but with a return of over 70% mobility in other joints the subject felt hip surgery now to be worth consideration. The one non-responsive subject proved to have cirrhosis of the liver, which may have been the reason for her inability to respond to treatment.. Further investigation is necessary to determine the role of liver function in this protocol.

GROUP # 3: Mild to moderately severe rheumatoid arthritis

In Group #3, fourteen subjects presenting with mild to moderately severe rheumatoid arthritis were supplied with 24 capsules, two 75mg capsules to be taken each morning and evening for six days. After three days of treatment eleven reported about 20% to 30% improvement in articulation and inflammation, and about 40% to 50% relief of arthritic pain. In these eleven subjects improvement continued rapidly over the next four days, approaching the 80% to 100% level. The remaining three subjects reported similar improvements by the end of the fourth day, with an overall improvement of 70% to 80% after seven days.

Most of the subjects continued to report minor additional improvement for one week or more even though they were no longer under treatment. However, six in this group began to experience the return of some mild arthritic symptoms after about three to four weeks. (Although not included as part of this study, all of the subjects in this group were treated again and their level of improvement has subsequently stabilised).

GROUP # 4: Severe to crippling osteo-arthritis

In Group #4, fourteen subjects presenting with severe to crippling osteo-arthritis were supplied with 50 capsules to be taken in two series, two 75mg capsules each morning and evening for seven days, with a seven day interval before repeating the same dosage for 5-1/2 more days. Three of these subjects were unable to walk and were accustomed to being transported by wheelchairs. The other eleven could move about with crutches, walkers, or canes. All presented with pain, inflammation, and marked deformation of nearly all interphalangeal and large joints. Four presented with limited lumbar flexion and pain in the vertebral column. Ten had difficulty grasping and manipulating common objects.

After four days of treatment ten in this group reported 30% to 50% improvement in articulation and inflammation and about 40% to 60% relief of arthritic pain. In these ten subjects improvement continued rapidly over the next three days, reaching 80% to 100% by the end of seven days. One reported no perceptible change.

On the fourteenth day, at the end of the one-week interval without treatment, nine subjects reported continuing minor improvement, four reported maintaining their improved status, and one continued to show no improvement. Treatment was resumed on the fifteenth day for 5-1/2 more days.

By the end of the treatment period eleven subjects reported 80% to 100% relief of pain with a return of 80% to 100% mobility. Two subjects reported 70% to 80% return of articular mobility with a 70% to 90% reduction of arthritic pain. The one non- responsive subject proved to have previous liver damage as a result of sports-related steroid abuse. Further studies are necessary to determine the role of liver function in this protocol.

SUMMARY

The results of this study lead to several conclusions regarding its five principal objectives:

1.) Optimum dosage levels appear to be equal for all three types of arthritis investigated: osteo-arthritis, rheumatoid arthritis, and reactive psoriatic arthritis. This is evidenced by the gradual return of minor arthritis symptoms in several of those treated with only 16 or 24 capsules, and no regression in those treated with 50 capsules in two series separated by one week without treatment.

2.) Dosage level requirements appear to be equal irrespective of the severity of the subject's condition.

3.) Initial response time for minor improvement appears to vary from two to seven days irrespective of the severity of the subject's condition.

4.) The time for maximum attainable response appears to vary from seven to twenty-one days, resulting in 70% to 100% overall improvement. (Apart from this study, three of the most severely afflicted subjects were treated again after a five-week interval, resulting in an additional 10% to 20% overall improvement.)

5.) The two non-responding subjects both proved to have suffered previous damage to the liver from steroid or alcohol abuse, indicating that impaired liver function may preclude success with this protocol.

In addition, it was evident that for many subjects the relief of inflammation resulted in marked improvement in joint deformation.

(This study was conducted at several different sites after the model prepared by the San Diego Clinic.)

CASE HISTORIES

Here are some condensed case highlights from The San Diego Clinic Trials

From case history #38: Medical Doctor. Pain and stiffness in hands for several years. Unable to perform simple office surgery. One day of CMO brought relief. Dexterity and fine surgical ability returned gradually. Ordered CMO for his patients.

From case history #39: Male. Medical Doctor/psychiatrist. This physician complained of persistent pains along his spine and in his feet. He became completely free of pain in both the spine and feet within two days of starting CMO capsules. Remission continues.

From case history # 33: Medical Doctor. Auto wreck ten years earlier damaged hip, caused limp and arthritis. CMO relieved pain permanently in one day for the first time after many years. The limp problem is irreparable. Ordered CMO for his patients.

From case history # 06: Female. Age 45. Arthritis attack worsened rapidly over a period of only seven months. Required a wheelchair to be moved about. Frequently unable to leave bed in mornings because of debilitating pain. Seeking relief, she worked with a personal trainer. She was incapable of holding a five pound weight, unable to make a fist. Saw immediate improvement with CMO in just three days. Two weeks after the first, she took a second course of CMO. She is now able to perform a full workout, has no difficulty making a fist, wakes in the mornings free of pain, and has resumed a normal active life.

From case history # 29: Female. Age 63. Despite devoted adherence to a truly natural diet, suffered severe osteo-arthritis in most joints for over ten years. Woke to agonising pain. Even simple chores were arduous. CMO brought total relief in ten days.

From case history # 24: Female. Age 50. Family history of arthritis. Pain in shoulders. Severe pain, limited mobility, and gross swelling in hands and fingers. By the third day of CMO, hands were free of pain, mobility had increased immensely, and finger swelling decreased so dramatically she had to have all her rings re-sized. Repeated treatment three weeks later. Totally free of pain and inflammation since. For the first time in many years, she was recently delighted to experience a pain-free skiing holiday.

From case history # 22: Female. Clinically obese. Arthritis in neck and spinal column resulting in joint mobility limitations. Despite impaired liver function which frequently inhibits the benefits of CMO, her range of motion increased by 100% within one week. A repeat course of CMO two weeks later has resulted in even greater and continuing improvement.

From case history # 03: Male. Age 32. Rheumatoid arthritis at age 25. Family history of arthritis. Seven years of pain in hands, shoulders, legs, and ankles. Although subject saw substantial improvement after taking CMO for three days, he did not experience complete relief with continuing remission for about two weeks. He has subsequently enjoyed skiing holidays and has been able to return to playing golf without the discomfort of any pain

From case history # 17: Female. Age 60. Physician. Relentless pain from hip injury one year prior. Diverse treatments and medicines brought little relief. With CMO and massages to reduce edema and improve muscle activity, her pain gradually diminished in two weeks. Now remains completely free of pain.

From case history # 15: Lifelong athlete. Arthritic pain and/or stiffness in hands, feet, knees, neck, and shoulders _ especially with exposure to the cold. With three days of CMO, was totally free of pain with dramatically increased articulation in the joints. Further improved mobility came with a repeat set of CMO three weeks later. He now enjoys skiing and other activities with the vigour and delight he lost so many years ago.

From case history # 11: Male. Age 58. Ex football player. Clinically obese. Had knee surgery three times about 15 years ago. Had extreme pain upon lying down. Often slept in a recliner chair instead. With his first evening dose of CMO capsules, he slept soundly and arose the next morning completely free of pain. He has enjoyed continuing pain-free remission ever since the first day.

From case history # 08: Male. Medical Doctor/psychiatrist. Pains in feet daily for over five years. With CMO almost constant pain disappeared within a day. Ordered CMO for his patients.

From case history #32: Female. Age 66. Rheumatoid arthritis rendered hands useless, gnarled, inflexible, agonisingly painful six years ago. Pain relieved and full use of hands restored after five days of CMO.

How to get the best out of CMO?

Suggested Use:

Take two or three (2-3) capsules in the morning, two or three (2-3) capsules at night (bedtime), until you finish all the capsules in 3-4 bottles of 60 capsules each. Do not drink anything but water for two hours before and one hour after taking your CMO capsules. Very Important: Do not take CMO with alcohol, caffeine or chocolate. This may render your CMO capsules totally ineffective. Following the recommended diet and suggested nutrients will improve effectiveness.

The manufacturer reports that the effect of CMO is cumulative. If you have take break in the protocol for any reason, you can resume at a later date to complete the course.

Most people do not require more than four bottles. For those who have not received full benefit, or if your symptoms return, you may need a further course.

Clinical trails have shown that people with liver problems do not get full benefit of CMO. All forms except gouty arthritis have responded in clinical trails and as reported by doctors and other professionals.

Recommended Diet:

The golden rule while taking CMO: To improve effectiveness, abstain from the use of alcohol, caffeine and chocolate during the entire period while taking CMO and for two weeks after taking your final capsules. This includes non-alcohol beer, coffee (even decaffeinated), black tea, colas or other caffeine containing substances. Consult your doctor before making radical changes to your diet.

Additional hints to improve effectiveness while taking CMO: Minimize or avoid eating Nightshades (tomatoes, potatoes, green, red and yellow bell peppers, and eggplant). Some users find it also helps to reduce the consumption of fats, oils, beans, lentils, citrus fruit, and all forms of wheat, rye, corn and barley during the protocol. You should remain on this diet for the entire period of protocol and the following two weeks for optimum results. Consult your doctor before making radical changes to your diet.

A diet for anyone with arthritis: As with all arthritis sufferers, it is best to avoid the "nightshade" group of vegetables whether you are taking CMO or not. Nightshades have been found to aggravate the arthritic condition. Consult your doctor before making radical changes to your diet.

Medications:

CMO does not interfere with any known medications or alter their effects. Medications do not interfere with the effects of CMO except in two cases, methotrexate and steroids.

Methotrexate: The prescription drug methotrexate or (Rheumatrex) will completely block the effects of CMO. Methotrexate is an immune suppressant, CMO is an immune modulator, to two actions are contradictory and the effects of CMO are blocked. Request that your doctor allow you to discontinue these drugs for at least one week prior to starting CMO. Consult with your physician before making any changes in your current medications.

Steroids: In some cases, cortisone or other steroids, have hindered the benefits of CMO. Because your liver is so busy processing them, you can't absorb the full benefits of CMO. If you are taking cortisone or other steroids, advise your doctor that it would be better to avoid them or reduce their dosage levels. If not ask him about taking half doses. Then as your pain disappears, you may request that he discontinue them completely. Consult with your physician before making any changes in your current medications.

Pain Medications: After taking CMO, you may find you no longer need pain medications. If wish to discontinue taking your pain medications, consult with your physician.

Nutritional Supplements: CMO does not interfere with the effects of nutritional supplements. Nutritional supplements do not interfere with the effects of CMO, except in some cases they may actually improve its effectiveness. In most cases there is no need for additional supplements. However, in a few cases, users report they have found the following protocols to help boost the effects of CMO when they felt they were receiving below average benefits. According to users, digestive enzymes are the single most popular way to help your body absorb CMO.

Digestive Enzymes: CMO may be taken with digestive enzymes to improve its effectiveness. They seem to aid in the assimilation of CMO through the digestive track. Enzyme mixtures that contain lipase, protease and amylase (such as Digase™) are recommended. Avoid combinations containing hydrochloric acid (HCL) or pancreatin. It is not necessary to take enzymes with meals, only with your CMO capsules.

Whey Protein: Although the general rule is to take CMO on an empty stomach with water, CMO capsules may also be taken with a whey protein drink and digestive enzymes to further improve it's effectiveness. This is a new protocol developed by a doctor who says that he has been getting very good results.

Cartilage Supplements: Pathaid - Glucosamine Complex, Chondroitin Sulfate Plus, Joint Vibrance, or similar substances may help to promote the regeneration of joint cartilage during and after CMO use. They may be taken during the CMO protocol as well as afterwards. This may promote the healing of your cartilage.

Fish Oils: Natural fish oil supplements (such as Omega Plus) have been highly recommended by Dr. Hunt in his book "Boom You're Well." They can act as a lubricant to reduce wear and tear on your healing joints. Many user report to us that within a week, they can feel the benefits of fish oil. This may be taken during the CMO protocol as well as afterwards.

Liver Cleansers: Users report that using a natural liver cleansing product (such as Hepa Plus) several days before starting CMO capsules may improve it's effectiveness. This is especially true among moderate to heavy users of alcohol and those on strong medications. Such cleansers among others may include milk thistle extract, selenium, and phosphatidylcholine.

Detoxification: Some persons who have been ill for many years may sometimes experience the effects of a "detoxification reaction". This can occur when the body is unable to eliminate large amounts of newly cleansed toxins fast enough. If after a few days of taking CMO, feelings of nausea and or weakness appear, feel free to stop taking the capsules until the body cleanses and the symptoms are gone. This generally takes only a couple of days. Then continue with your CMO capsules as before. Since the beneficial effects are cumulative, any temporary interruptions will not affect the final outcome. Although rare, a few people with rheumatoid arthritis have felt a short-term, temporary worsening of their symptoms. This has lasted for a few days after which their progress has then continued normally. Sometimes it may appear that the full benefits of CMO have occurred early in the treatment. However it is advised to take all four bottles to assure the complete, long-lasting benefits of CMO.

A short note about arthritis

What is arthritis?

There are so many forms of arthritis that they can not all be presented here. According to the Arthritis Foundation of America (similar to Arthritis and Rheumatism Council, here), arthritis refers to more than 100 different diseases that cause pain, swelling and limited movement in joints and connective tissue throughout the body. It is usually chronic, meaning that it lasts a lifetime. The disease process also varies depending on the form of arthritis.

The three most prevalent forms are osteo-arthritis (OA), fibromyalgia and rheumatoid arthritis (RA). Osteo-arthritis is a degenerative joint disease in which the cartilage that covers the ends of bones in the joint deteriorates, causing pain and loss of movement as bone begins to rub against bone. In fibromyalgia, widespread pain affects the muscles and attachments to the bone. In rheumatoid arthritis the joint lining becomes inflamed as part of the body's immune system activity. The chronic inflammation causes deterioration of the joint and the pain and limited movement. You should be aware that osteo-arthritis or degenerative joint disease is the most common. CMO is effective on all forms of arthritis except gouty arthritis. The following is what the Arthritis Foundation of New York has to say about osteo-arthritis:

Osteo-arthritis or Degenerative Joint Disease: Arthritis refers to inflammation of the joint space. Osteo-arthritis also known as degenerative joint disease (DJD) is a slow and progressive form of degenerative arthritis that is seen most commonly in the elderly. Joints that have been previously injured (fractured or severely sprained), or subject to chronic stress (obesity or repetitive overuse syndrome) can also lead to premature degenerative changes in the younger patient.

The joints are lined with a material known as cartilage, which provides a smooth surface over which the joint can "glide" without difficulty. Degenerative arthritis causes destruction of the cartilage, predominantly in the weight bearing (high stress) joints of the body.

The main joints affected by DJD are the hands, hips, knees, cervical (neck) spine, and the lumbar (lower back) spine. Almost all patients over the age of 60 have some degree of DJD in one or more of these locations.

Common symptoms and the appearance of degenerative arthritis include a long history (over years) of episodic joint pain with occasional mild swelling to the joints. DJD does not necessarily produce the remarkable joint swelling, warmth, and tenderness as that of septic arthritis or rheumatoid arthritis. Overweight patients tend to have more low back, hip, and knee problems.

Cervical (or lumbar) degenerative joint disease will commonly result in progressive neck (or back) pain and stiffness. More advanced cases can result in impingement (compression) of exiting nerve roots, giving rise to numbness, tingling, or weakness to the upper (or lower) extremities.

Evaluation will include a history and physical examination. X-rays of the involved joints will show characteristic changes associated with DJD. Serologic tests (rheumatoid factor) may be performed to exclude the possibility of rheumatoid arthritis. Magnetic resonance scanning of the neck or back will be performed in cases where nerve root compression is suspected.

Treatment includes aspirin or non-steroidal anti-inflammatory agents (ibuprofen) for acute attacks and long-term symptomatic management. Chiropractic manual manipulation and acupuncture are recognised alternatives. In cases of obesity, weight reduction should be considered part of the treatment. Physical therapy to strengthen muscles can take stress off the joints and will have a dramatic effect on decreasing the arthritic pain (and progression of the disease).

Artificial joint replacement has been used successfully for advanced disease in the knees (knee arthroplasty), hips (hip arthroplasty), shoulders, elbows, and joints of the hand and wrist. An Orthopaedic Surgeon is the expert in the management of this common problem. Cases involving nerve compression will require referral to a Neurosurgeon.

Note: The last 2 paragraphs list what were the most common remedies available to victims of arthritis before the development of CMO. Given the choice of surgery, a life-time of pain pills or taking CMO only once, it is easy to see why CMO is so popular.

What causes arthritis?

Dr. Sands the Director of the San Diego Clinic explains it by saying: "The numerous theories about what causes arthritis have filled hundreds of volumes. But one thing we do know is that the arthritic process is regulated by "Memory T-cells" which have been erroneously programmed, causing attacks on your own joints and cartilage. In osteo-arthritis, this faulty programming usually results from physical damage (like a fall, sports injury, vehicle accident, long-term strenuous physical work or sports activities, or any frequent jarring or shocking of the joints, etc.).

The damage results in an immune response involving the memory T-cells, producing attacks against the affected joints. Unfortunately, there's no 'stop button' or 'end program' command in the memory T-cells and the attack continues against healthy cartilage and joints as well. That's why we call arthritis an auto-immune disease - because your body is attacked by your own immune cells. Although the various forms of rheumatoid arthritis are usually caused by some infective micro-organism, memory T-cells are again involved in the same arthritic process. Without CMO, it continues to worsen."

  Health Products Distributors, Inc.
Bringing Balance to Life Naturally
PO Box 5600, Oracle, AZ 85623
Service: 520-896-2198